Alemtuzumab induction and belatacept maintenance in marginal pathology renal allografts.

Sparkes, Tracy; Ravichandran, Bharath; Opara, Onumara; Ugarte, Richard; Drachenberg, Cinthia B; Philosophe, Benjamin; Bromberg, Jonathan S; Barth, Rolf N

Sparkes, Tracy; Ravichandran, Bharath; Opara, Onumara; Ugarte, Richard; Drachenberg, Cinthia B; Philosophe, Benjamin; Bromberg, Jonathan S; Barth, Rolf N.

Affiliation

Sparkes T; Department of Pharmacy, University of Maryland Medical Center, Baltimore, Maryland.
Ravichandran B; Department of Pharmacy, University of Maryland Medical Center, Baltimore, Maryland.
Opara O; Department of Transplant, University of Maryland School of Medicine, Baltimore, Maryland.
Ugarte R; Department of Transplant, University of Maryland School of Medicine, Baltimore, Maryland.
Drachenberg CB; Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland.
Philosophe B; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Bromberg JS; Department of Transplant, University of Maryland School of Medicine, Baltimore, Maryland.
Barth RN; Department of Transplant, University of Maryland School of Medicine, Baltimore, Maryland.

Clin Transplant ; 33(6): e13531, 2019 06.

Article in En | MEDLINE | ID: mdl-30866104

Subject(s)

Abatacept/pharmacology; Alemtuzumab/pharmacology; Graft Rejection/drug therapy; Graft Survival/drug effects; Induction Chemotherapy/methods; Kidney Transplantation/adverse effects; Maintenance Chemotherapy/methods; Antineoplastic Agents, Immunological/pharmacology; Female; Follow-Up Studies; Glomerular Filtration Rate; Graft Rejection/etiology; Graft Rejection/pathology; Humans; Immunosuppressive Agents/therapeutic use; Kidney Failure, Chronic/surgery; Kidney Function Tests; Male; Middle Aged; Pilot Projects; Postoperative Complications/drug therapy; Postoperative Complications/etiology; Postoperative Complications/pathology; Prognosis; Prospective Studies; Risk Factors; Transplantation, Homologous

Key words

Immunosuppressant; donors and donation: extended criteria; fusion proteins and monoclonal antibodies: alemtuzumab; fusion proteins and monoclonal antibodies: belatacept; kidney (allograft) function/dysfunction

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Kidney Transplantation / Induction Chemotherapy / Maintenance Chemotherapy / Abatacept / Alemtuzumab / Graft Rejection / Graft Survival Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: Clin Transplant Journal subject: TRANSPLANTE Year: 2019 Type: Article

Fulltext

XML

PubMed Links

Search on Google